Core Viewpoint - Arch Biopartners Inc. has appointed Dr. Patrick Vink as the new Chairman of the Board of Directors, effective January 15, 2026, following the retirement of Claude Allary [1][5]. Company Leadership - Dr. Patrick Vink has extensive experience in the pharmaceutical industry, having served as an advisor since 2015 and held various board positions in public and private companies across North America and Europe [2]. - His previous roles include Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, where he oversaw operations until its $9.5 billion acquisition by Merck in 2015 [3]. - Dr. Vink has a history with Arch Biopartners, having served as a director from December 2016 to December 2019 and as a Strategic Advisor thereafter [3]. Company Development - The appointment of Dr. Vink is seen as beneficial for Arch Biopartners as the company advances its acute kidney injury Phase II trials and chronic kidney disease program [4]. - The company is focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), targeting serious unmet needs affecting over 800 million people globally [7]. Board Changes - Claude Allary, who has been a director since 2014, has retired, contributing significantly to Arch's evolution into a leading kidney therapeutics company [5][6].